| Literature DB >> 29251725 |
Valeria Cagno1,2,3, Patrizia Andreozzi4,5, Marco D'Alicarnasso6, Paulo Jacob Silva2, Marie Mueller2, Marie Galloux7, Ronan Le Goffic7, Samuel T Jones2,8, Marta Vallino9, Jan Hodek10, Jan Weber10, Soumyo Sen11, Emma-Rose Janeček2, Ahmet Bekdemir2, Barbara Sanavio12, Chiara Martinelli4, Manuela Donalisio1, Marie-Anne Rameix Welti13,14, Jean-Francois Eleouet7, Yanxiao Han11, Laurent Kaiser15, Lela Vukovic16, Caroline Tapparel3,15, Petr Král11,17, Silke Krol12,18, David Lembo1, Francesco Stellacci2,19.
Abstract
Viral infections kill millions yearly. Available antiviral drugs are virus-specific and active against a limited panel of human pathogens. There are broad-spectrum substances that prevent the first step of virus-cell interaction by mimicking heparan sulfate proteoglycans (HSPG), the highly conserved target of viral attachment ligands (VALs). The reversible binding mechanism prevents their use as a drug, because, upon dilution, the inhibition is lost. Known VALs are made of closely packed repeating units, but the aforementioned substances are able to bind only a few of them. We designed antiviral nanoparticles with long and flexible linkers mimicking HSPG, allowing for effective viral association with a binding that we simulate to be strong and multivalent to the VAL repeating units, generating forces (∼190 pN) that eventually lead to irreversible viral deformation. Virucidal assays, electron microscopy images, and molecular dynamics simulations support the proposed mechanism. These particles show no cytotoxicity, and in vitro nanomolar irreversible activity against herpes simplex virus (HSV), human papilloma virus, respiratory syncytial virus (RSV), dengue and lenti virus. They are active ex vivo in human cervicovaginal histocultures infected by HSV-2 and in vivo in mice infected with RSV.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29251725 DOI: 10.1038/nmat5053
Source DB: PubMed Journal: Nat Mater ISSN: 1476-1122 Impact factor: 43.841